| CROs are strategic partners for bio-pharma companies; success hinges on their data-driven AI operating systems and global regulatory response capabilities
| Korean CROs are expanding into the global market, positioning themselves as essential clinical partners through digital and regulatory innovation
| JNPMEDI drives clinical trial efficiency with its innovative platform for the digital age
Reporter Kwon-Gu Lee │ [email protected]
As Korea grows into a global powerhouse for clinical trials, the role of Contract Research Organizations (CROs), which cover the entire new drug development lifecycle, is also expanding. They are establishing themselves as key players in the market by leveraging advanced AI-based digital technologies.
Within this trend, domestic CROs are gaining attention through AI, digital technology, and specialized expertise. They are now emerging as true collaborators, equipped with data-driven operating systems and global regulatory response capabilities.
Verified technical expertise that meets global regulatory standards is now essential when selecting a CRO. Consequently, domestic CROs are actively introducing AI-based platforms and automated data management systems to meet this demand.
In fact, over 30 new AI and machine-learning-based clinical trials have been initiated annually from 2022 to 2024. This trend of digital transformation is already spreading across the entire bio-pharma industry.
CRO competitiveness now hinges on more than just speed or efficiency. It is determined by data reliability, global regulatory compliance, and digital-first operations.
In keeping with these changes, JNPMEDI is gaining attention for its innovative role in leading digital transformation.
JNPMEDI, an AI-powered clinical trial consulting firm, has built a system that can manage the entire clinical trial lifecycle through its proprietary clinical trial data platform, 'Maven Clinical Cloud.' By adding AI-based data management capabilities, it is playing a pivotal role in the digital clinical trial ecosystem. Its ability to provide flexible, on-demand services that respond to the entire bio-pharma industry—including decentralized clinical trials, product development, regulatory approval, and out-licensing—is recognized as a key competitive advantage.
Recently, the company attracted attention with the launch of 'Maven Converter,' a solution for converting clinical data based on the CDISC (Clinical Data Interchange Standard Consortium) SDTM (Study Data Tabulation Model) standard. Maven Converter provides a No-Code environment that allows for easy conversion of raw data to the international SDTM standard.
It also supports the generation of metadata according to the Define-XML format and an automatic re-conversion function when raw data is changed. This is highly regarded for minimizing manual work, maximizing efficiency, and dramatically lowering entry barriers.
Furthermore, 'Maven X,' a clinical trial collaboration solution for real-time monitoring of clinical trial status, is undergoing continuous advancement. This solution is designed to consistently manage the entire process from clinical trial contract to completion based on standard operating procedures (SOPs). It also aims to provide criteria for quantifying project-specific performance.
In particular, the company expects that with its integration with Maven TMF, a solution designed to digitize paper-based TMFs for efficient storage, access, tracking, and management of documents and data, fragmented information can be organically integrated. This is expected to position the solution as a core tool that simultaneously improves CRO operational quality and efficiency.
Earlier, JNPMEDI showcased 'Maven Coder Express,' an automated data coding system utilizing generative AI technology, leading the advancement of digital-based solutions.
Developed on Amazon Web Services (AWS)'s generative AI platform, Amazon Bedrock, the solution converts descriptive data entered by researchers into standardized medical terminology (MedDRA), shortening work hours. It accurately codes and manages clinical data, adverse event reports, and more in standardized terms.
YoungYong Park, CTO of JNPMEDI, stated, "JNPMEDI is becoming a vital partner in biopharma innovation through digital, end-to-end clinical trial solutions."
He added, "In March, JNPMEDI was selected as an AWS Authorized Managed Service Provider (MSP), receiving global-level recognition for our cloud infrastructure operation capabilities and technical reliability. This confirms our ability to meet stringent compliance standards—such as data privacy laws, GCP, and GMP—essential to the bio-pharma industry. We anticipate a synergy from our flexible, cloud-based resource management and the introduction of AI technology."
✔️ Read the original article : LINK
| CROs are strategic partners for bio-pharma companies; success hinges on their data-driven AI operating systems and global regulatory response capabilities
| Korean CROs are expanding into the global market, positioning themselves as essential clinical partners through digital and regulatory innovation
| JNPMEDI drives clinical trial efficiency with its innovative platform for the digital age
Reporter Kwon-Gu Lee │ [email protected]
As Korea grows into a global powerhouse for clinical trials, the role of Contract Research Organizations (CROs), which cover the entire new drug development lifecycle, is also expanding. They are establishing themselves as key players in the market by leveraging advanced AI-based digital technologies.
Within this trend, domestic CROs are gaining attention through AI, digital technology, and specialized expertise. They are now emerging as true collaborators, equipped with data-driven operating systems and global regulatory response capabilities.
Verified technical expertise that meets global regulatory standards is now essential when selecting a CRO. Consequently, domestic CROs are actively introducing AI-based platforms and automated data management systems to meet this demand.
In fact, over 30 new AI and machine-learning-based clinical trials have been initiated annually from 2022 to 2024. This trend of digital transformation is already spreading across the entire bio-pharma industry.
CRO competitiveness now hinges on more than just speed or efficiency. It is determined by data reliability, global regulatory compliance, and digital-first operations.
In keeping with these changes, JNPMEDI is gaining attention for its innovative role in leading digital transformation.
JNPMEDI, an AI-powered clinical trial consulting firm, has built a system that can manage the entire clinical trial lifecycle through its proprietary clinical trial data platform, 'Maven Clinical Cloud.' By adding AI-based data management capabilities, it is playing a pivotal role in the digital clinical trial ecosystem. Its ability to provide flexible, on-demand services that respond to the entire bio-pharma industry—including decentralized clinical trials, product development, regulatory approval, and out-licensing—is recognized as a key competitive advantage.
Recently, the company attracted attention with the launch of 'Maven Converter,' a solution for converting clinical data based on the CDISC (Clinical Data Interchange Standard Consortium) SDTM (Study Data Tabulation Model) standard. Maven Converter provides a No-Code environment that allows for easy conversion of raw data to the international SDTM standard.
It also supports the generation of metadata according to the Define-XML format and an automatic re-conversion function when raw data is changed. This is highly regarded for minimizing manual work, maximizing efficiency, and dramatically lowering entry barriers.
Furthermore, 'Maven X,' a clinical trial collaboration solution for real-time monitoring of clinical trial status, is undergoing continuous advancement. This solution is designed to consistently manage the entire process from clinical trial contract to completion based on standard operating procedures (SOPs). It also aims to provide criteria for quantifying project-specific performance.
In particular, the company expects that with its integration with Maven TMF, a solution designed to digitize paper-based TMFs for efficient storage, access, tracking, and management of documents and data, fragmented information can be organically integrated. This is expected to position the solution as a core tool that simultaneously improves CRO operational quality and efficiency.
Earlier, JNPMEDI showcased 'Maven Coder Express,' an automated data coding system utilizing generative AI technology, leading the advancement of digital-based solutions.
Developed on Amazon Web Services (AWS)'s generative AI platform, Amazon Bedrock, the solution converts descriptive data entered by researchers into standardized medical terminology (MedDRA), shortening work hours. It accurately codes and manages clinical data, adverse event reports, and more in standardized terms.
YoungYong Park, CTO of JNPMEDI, stated, "JNPMEDI is becoming a vital partner in biopharma innovation through digital, end-to-end clinical trial solutions."
He added, "In March, JNPMEDI was selected as an AWS Authorized Managed Service Provider (MSP), receiving global-level recognition for our cloud infrastructure operation capabilities and technical reliability. This confirms our ability to meet stringent compliance standards—such as data privacy laws, GCP, and GMP—essential to the bio-pharma industry. We anticipate a synergy from our flexible, cloud-based resource management and the introduction of AI technology."
✔️ Read the original article : LINK